BofA analyst Geoff Meacham lowered the firm’s price target on Neumora Therapeutics (NMRA) to $7 from $22 and keeps a Buy rating on the shares.

Neumora Therapeutics Inc.’s stock tumbled 80% Thursday, after the clinical-stage biotech said a late-stage trial of a ...

Neumora Therapeutics, Inc. (NASDAQ:NMRA – Get Free Report) saw some unusual options trading on Monday. Stock traders acquired ...

Neumora Therapeutics Inc (NMRA) stock saw a modest uptick, ending the day at $2.17 which represents a slight increase of $0.20 or 10.15% from the prior close of $1.97. The stock opened at $2.23 and ...

Neumora Therapeutics' lead candidate, navacaprant, failed to meet primary and secondary endpoints in its Phase 3 KOASTAL-1 ...

Neumora Therapeutics’ big bet on a new era of neuroscience has delivered an age-old result. The first of three late-stage ...

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Neumora Therapeutics, Inc. (NMRA – Research Report) and ...

Key Takeaways Neumora Therapeutics reported its experimental depression drug didn't meet expectations, and shares plunged.The ...

Royal Bank of Canada cut shares of Neumora Therapeutics (NASDAQ:NMRA – Free Report) from an outperform rating to a sector ...

Neumora Therapeutics stock collapsed Thursday after its experimental depression treatment failed in the first of three ...

Neumora Therapeutics Inc (NMRA) stock saw a decline, ending the day at $1.97 which represents a decrease of $-8.63 or -81.42% from the prior close of $10.6. The stock opened at $1.88 and touched a low ...

Neumora Therapeutics (NMRA) crashed after its Phase 3 study for its lead asset navacaprant in major depressive disorder ...